Brought to you by 
Forest to co-develop Nabriva's BC3781; gets option to buy company--deal later terminated
27 Oct 2020
Executive Summary
Infectious disease-focused Austrian firm Nabriva Therapeutics AG has granted US specialty pharmaco Forest Laboratories Inc. rights to co-develop its Phase IIb antibacterial candidate BC3781.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest to co-develop Nabriva's BC3781; gets option to buy company--deal later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice